These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27492980)

  • 1. Complement C3a predicts outcome in cardiac resynchronization therapy of heart failure.
    Széplaki G; Boros AM; Szilágyi S; Osztheimer I; Jenei Z; Kosztin A; Nagy KV; Karády J; Molnár L; Tahin T; Zima E; Gellér L; Prohászka Z; Merkely B
    Inflamm Res; 2016 Dec; 65(12):933-940. PubMed ID: 27492980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ratio of the neutrophil leucocytes to the lymphocytes predicts the outcome after cardiac resynchronization therapy.
    Boros AM; Széplaki G; Perge P; Jenei Z; Bagyura Z; Zima E; Molnár L; Apor A; Becker D; Gellér L; Prohászka Z; Merkely B
    Europace; 2016 May; 18(5):747-54. PubMed ID: 25972301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population.
    Sokal A; Lenarczyk R; Kowalski O; Mitrega K; Pluta S; Stabryla-Deska J; Streb W; Urbanik Z; Krzeminski TF; Kalarus Z
    Heart Rhythm; 2016 May; 13(5):1088-1095. PubMed ID: 26776557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperuricemia predicts adverse clinical outcomes after cardiac resynchronization therapy.
    Perge P; Boros AM; Zima E; Gellér L; Merkely B; Széplaki G
    Scand Cardiovasc J; 2018 Oct; 52(5):250-255. PubMed ID: 30714413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle branch block patients.
    Kosztin A; Kutyifa V; Nagy VK; Geller L; Zima E; Molnar L; Szilagyi S; Ozcan EE; Szeplaki G; Merkely B
    Europace; 2016 Apr; 18(4):550-9. PubMed ID: 26116830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, echocardiographic, and neurohormonal response to cardiac resynchronization therapy: are they interchangeable?
    Hoogslag GE; Höke U; Thijssen J; Auger D; Marsan NA; Wolterbeek R; Holman ER; Schalij MJ; Bax JJ; Verwey HF; Delgado V
    Pacing Clin Electrophysiol; 2013 Nov; 36(11):1391-401. PubMed ID: 23826659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of the Red Blood Cell Distribution Width Improves the Risk Prediction in Cardiac Resynchronization Therapy.
    Boros AM; Perge P; Jenei Z; Karády J; Zima E; Molnár L; Becker D; Gellér L; Prohászka Z; Merkely B; Széplaki G
    Dis Markers; 2016; 2016():7304538. PubMed ID: 26903690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study.
    Berger R; Shankar A; Fruhwald F; Fahrleitner-Pammer A; Freemantle N; Tavazzi L; Cleland JG; Pacher R
    Eur Heart J; 2009 Sep; 30(17):2109-16. PubMed ID: 19493864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic importance of natriuretic peptides and atrial fibrillation in patients receiving cardiac resynchronization therapy.
    Smit MD; Maass AH; Hillege HL; Wiesfeld AC; Van Veldhuisen DJ; Van Gelder IC
    Eur J Heart Fail; 2011 May; 13(5):543-50. PubMed ID: 21330294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac resynchronization therapy in patients with chronic heart failure is associated with anti-inflammatory and anti-remodeling effects.
    Stanciu AE; Vatasescu RG; Stanciu MM; Iorgulescu C; Vasile AI; Dorobantu M
    Clin Biochem; 2013 Feb; 46(3):230-4. PubMed ID: 23159290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The prognostic role of extremely high levels of the B-type natriuretic prohormone with regard to the in-hospital mortality of patients hospitalized for heart failure].
    Bózsik B; Nagy E; Somlói M; Tomcsányi J
    Orv Hetil; 2017 May; 158(20):779-782. PubMed ID: 28502208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.
    Cleland J; Freemantle N; Ghio S; Fruhwald F; Shankar A; Marijanowski M; Verboven Y; Tavazzi L
    J Am Coll Cardiol; 2008 Aug; 52(6):438-45. PubMed ID: 18672164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score.
    Scrutinio D; Ammirati E; Guida P; Passantino A; Raimondo R; Guida V; Sarzi Braga S; Pedretti RF; Lagioia R; Frigerio M; Catanzaro R; Oliva F
    Int J Cardiol; 2013 Oct; 168(3):2120-6. PubMed ID: 23395457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
    Wolsk E; Claggett B; Pfeffer MA; Diaz R; Dickstein K; Gerstein HC; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Solomon SD; Tardif JC; Køber L
    J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28554908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy.
    van Diepen S; Newby LK; Lopes RD; Stebbins A; Hasselblad V; James S; Roe MT; Ezekowitz JA; Moliterno DJ; Neumann FJ; Reist C; Mahaffey KW; Hochman JS; Hamm CW; Armstrong PW; Granger CB; Theroux P;
    Int J Cardiol; 2013 Oct; 168(3):2127-33. PubMed ID: 23394896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of atrioventricular optimization on circulating N-terminal pro brain natriuretic peptide following cardiac resynchronization therapy.
    Shanmugam N; Campos AG; Prada-Delgado O; Bizrah M; Valencia O; Jones S; Collinson P; Anderson L
    Eur J Heart Fail; 2013 May; 15(5):534-42. PubMed ID: 23388091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decrease of plasma N-terminal pro beta-type natriuretic peptide as a predictor of clinical improvement after cardiac resynchronization therapy for heart failure.
    Ding LG; Hua W; Zhang S; Chu JM; Chen KP; Wang Y; Wang FZ; Chen X
    Chin Med J (Engl); 2009 Mar; 122(6):617-21. PubMed ID: 19323922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventricular lead separation is critical for NT-proBNP reduction after cardiac resynchronization therapy.
    Lang NN; Badar AA; Pettit SJ; Templeton S; Connelly DT; Gardner RS
    Biomark Med; 2014; 8(6):797-806. PubMed ID: 25224936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of myeloperoxidase plasma levels as a predictor for cardiac resynchronization therapy response.
    Sultan A; Wörmann J; Lüker J; V D Bruck J-; Plenge T; Rudolph V; Klinke A; Heijman J; Mollenhauer M; Ravekes T; Baldus S; Steven D
    Clin Res Cardiol; 2021 Aug; 110(8):1173-1180. PubMed ID: 32564144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study.
    Beaudoin J; Singh JP; Szymonifka J; Zhou Q; Levine RA; Januzzi JL; Truong QA
    Can J Cardiol; 2016 Dec; 32(12):1478-1484. PubMed ID: 27527259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.